Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.82 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 71.01 | Oscillator | Neutral |
| Williams %R (14) | -27.71 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.26 (Hist 0.13) | Oscillator | Strong Buy |
| Average Directional Index (14) | 22.03 (+DI 27.0 / -DI 17.7) | Trend | Buy |
Current price $25.30
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 5, 26 |
| EMA 20 | 24.70 | MA | Buy |
| SMA 20 | 24.48 | MA | Strong Buy |
| EMA 50 | 24.43 | MA | Strong Buy |
| SMA 50 | 24.77 | MA | Buy |
| SMA 200 | 21.23 | MA | Strong Buy |
| Citigroup |
| maintain |
| Neutral |
| Neutral |
| Jul 31, 26 | TD Cowen | maintain | Hold | Hold |
| Jul 31, 26 | Citigroup | upgrade | Sell | Neutral |
| Jul 31, 26 | Stifel | maintain | Hold | Hold |
| Jul 31, 26 | Wells Fargo | maintain | Equal Weight | Equal Weight |
| Jul 28, 26 | UBS | maintain | Neutral | Neutral |
| Jul 28, 26 | Stifel | maintain | Hold | Hold |
| Jul 27, 26 | TD Cowen | maintain | Hold | Hold |
| Jul 15, 26 | Goldman Sachs | maintain | Neutral | Neutral |
TTM vs. 5-year historical average (annual ratios)
| Metric | BAX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -12.4x | -0.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 12.3x | EPS est. 2.05 | Discount |
| Price / Book | 2.1x | 3.0x | Discount |
| Price / Sales | 1.1x | 2.1x | Discount |
| EV / EBITDA | 27.5x | 13.6x | Elevated |
| Return on equity | -16.6% | — | Weak |
| Gross margin | 30.1% | 36.3% | Below hist. |
| Debt / Equity | 1.56 | 2.04 | Levered |
| Piotroski / Altman Z | 4/9 | Z 2.30 | Grey zone |
Discounted cash flow model
Stock news · updated daily
Cohen Klingenstein LLC acquired a new position in shares of Baxter International Inc. (NYSE: BAX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,728 shares of the medical instruments supplier's stock, valued at approximately $497,000. Several other institutional investors and
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of recent ratings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2026 financial results on Thursday, October 29, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/analyst/129835310?pwd=2FG2j7ZZ to pre-register for the call and receive the call information.This call is also being webcast and can be accessed through Baxter's website at www.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes. Based on a survey of 150 information technology (IT) and nursing leaders, the report examines how hospitals are progressing along a “connected hospital” journey by identifying four distin.
Baxter International Inc. (NYSE: BAX - Get Free Report) has earned a consensus recommendation of "Hold" from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have given a buy rating to the company.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | 0.37 | 0.56 | Beat 52.8% | $2.96B |
| Apr 30, 2026 | 0.31 | 0.36 | Beat 15.8% | $2.70B |
| Feb 12, 2026 | 0.53 | 0.44 | Miss -17.0% | $2.97B |
| Oct 30, 2025 | 0.60 | 0.69 | Beat 15.0% | $2.83B |
| Jul 31, 2025 | 0.60 | 0.59 | Miss -1.7% | $2.81B |
| May 1, 2025 | 0.48 | 0.55 | Beat 13.8% | $2.63B |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Rogers Terence John | officer: EVP and CFO | 0 | — | |
| Sep 15, 26 | Heine Bernard | officer: AVP, Finance InterimCAO&Cntrlr | 0 | — | |
| Sep 1, 26 | Teaff James | officer: President, CCS | F-InKind | 750 @ $25.48 | $19.11K |
| Sep 2, 26 | Hider Andrew P. | director, officer: President and CEO | F-InKind | 54,276 @ $25.70 | $1.39M |
| Sep 2, 26 | Foster Julie | officer: President, Front Line Care | F-InKind | 2,098 @ $25.70 | $53.92K |
| May 5, 26 | Wilkes David S. | director | A-Award | 12,836 | — |
| May 5, 26 | Wendell Amy Mcbride | director | A-Award | 12,836 | — |
| May 5, 26 | Schlichting Nancy M | director | A-Award | 12,836 | — |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 3 | Oct 2, 2026 | 2026-10-02 16:02:11 | View |
| 3 | Sep 18, 2026 | 2026-09-18 16:04:16 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:19:37 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:18:10 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:16:39 | View |
| 8-K | Aug 19, 2026 | 2026-08-19 08:07:42 | View |
| 8-K | Aug 18, 2026 | 2026-08-18 17:00:50 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 17:22:22 | View |
| 8-K | Aug 4, 2026 | 2026-08-04 08:32:33 | View |
| 10-Q | Jul 30, 2026 | 2026-07-30 16:45:57 | View |
Proxy statement (DEF 14A) disclosures